• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Science & Environment Medical Research

New research shows promise for targeted therapies for pediatric gliomas

July 31, 2025
in Medical Research
Reading Time: 6 mins read
A A
0
Dana-Farber Research Shows Promise for Targeted Therapies for Pediatric Gliomas
3
SHARES
7
VIEWS
Share on FacebookShare on Twitter


Dana-Farber Research Shows Promise for Targeted Therapies for Pediatric Gliomas
Expression of FGFR1 is found in neuronal and glial lineage cell types in brain development. a Expression of FGFR1 in bulk RNA-seq across lifespan in human forebrain (n = 55) (left) and hindbrain (n = 59) (right). X-axis denotes sample age, measured in natural log of weeks post conception, and x-axis tick values correspond to weeks in prenatal points and years in postnatal points. Vertical dashed line depicts birth. Y-axis depicts RPKM expression values. b, c UMAP representation of human embryo cells 4–5.5 weeks post conception. N = 7 embryos, 185k cells. b Left: Cells colored by neural progenitor cells annotated in the original study colored green. c Right: Cells colored by normalized expression of FGFR1. Color scale midpoint is set to the midpoint of maximum and minimum expression. d Detection rate (% of cells with expression >0) of FGFR1 expression in broad cell types of first trimester human brain. e Top 15 cell clusters by detection rate (% of cells with expression of >0) of Fgfr1 expression in developing mouse pons and forebrain. Cell clusters grouped by broad cell type. Credit: Nature Communications (2025). DOI: 10.1038/s41467-025-61820-z

A collaborative study between Dana-Farber Cancer Institute and the Broad Institute found that 8.9% of children with glioma, the most common form of pediatric brain tumor, have alterations in the fibroblast growth factor receptor (FGFR) family of proteins, and that these gliomas may be sensitive to existing U.S. Food and Drug Administration (FDA) approved inhibitors that broadly block FGFR.

The work opens the door to potential targeted therapy for these tumors, particularly for pediatric low-grade gliomas (pLGG), though more research is needed to improve the efficacy of these treatments and to test them in pediatric clinical trials. Currently there are no FDA-approved therapies or clinical trials specifically for FGFR-altered pediatric gliomas.

“This research was motivated by the patients we see in our Jimmy Fund Clinic and others around the world who have been diagnosed with pediatric gliomas with FGFR-alterations and want to know if existing targeted medicines are an option,” says co-senior author Pratiti (Mimi) Bandopadhayay, MBBS, PhD, a physician-scientist at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and an institute member at Broad.

“The results of this study have given us insights that will impact children with FGFR-altered gliomas seeking care in the clinic today.”

The research is published today in Nature Communications.

Similar research at Dana-Farber led to the recent approval of tovorafenib for childhood BRAF-altered gliomas.

“We’re following that same strategy with this research but with a focus on FGFR-altered pediatric gliomas,” says Bandopadhayay. “It is a real area of need for families.”

This study, which was also led by Dana-Farber pathologist and an associate member at Broad, Keith Ligon, MD, PhD, performed genomic analyses on 11,635 gliomas from three existing datasets across all ages. The analysis revealed that 8.9% of pediatric gliomas harbor FGFR alterations. The most common alterations found were in the FGFR1 and FGFR2 genes and included both point mutations and structural variants. The team concluded that FGFR1-altered pLGGs were the most frequent subgroup of FGFR-altered gliomas in children.

Co-first authors April Apfelbaum, PhD, and Eric Morin, MD, PhD, post-doctoral fellows in the Bandopadhayay lab, leveraged the genomic data to develop the first-ever models of FGFR-altered gliomas consisting of spherical collections of living FGFR-altered neural stem cells. They used the models to determine that FGFR alterations can induce the development of the tumors.

Tests of FGFR inhibitors in the preclinical models showed that the tumors were sensitive to the inhibitors.

“This is the first preclinical data showing that existing FGFR inhibitors might be viable therapeutics for FGFR-altered pediatric gliomas,” says Apfelbaum.

They followed their preclinical model tests with a retrospective look at a small number of cases of pediatric patients with FGFR-altered gliomas who were treated with FGFR inhibitors. They found that patients with pLGGs frequently experienced stable disease after treatment with these medicines.

PLGGs are the most common central nervous system cancer among children. Patients typically survive into adulthood after treatment because the tumors stop growing over time, but current standard treatment with chemotherapy and surgery result in long-term challenges including mental health disorders, vision changes or loss, seizures, and behavioral challenges.

“We are eager to find precision medicines with fewer side effects than current standard of care treatment for these patients,” says Bandopadhayay.

The team plans continued research to improve the efficacy and brain penetrance of FGFR inhibitors and to test these medicines in clinical trials. They also plan to investigate their finding that FGFR expression may play a role in normal brain development to determine if that finding should influence treatment strategies.

More information:
April A. Apfelbaum et al, A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas, Nature Communications (2025). DOI: 10.1038/s41467-025-61820-z

Provided by
Dana-Farber Cancer Institute


Citation:
New research shows promise for targeted therapies for pediatric gliomas (2025, July 31)
retrieved 31 July 2025
from https://medicalxpress.com/news/2025-07-therapies-pediatric-gliomas.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.




Dana-Farber Research Shows Promise for Targeted Therapies for Pediatric Gliomas
Expression of FGFR1 is found in neuronal and glial lineage cell types in brain development. a Expression of FGFR1 in bulk RNA-seq across lifespan in human forebrain (n = 55) (left) and hindbrain (n = 59) (right). X-axis denotes sample age, measured in natural log of weeks post conception, and x-axis tick values correspond to weeks in prenatal points and years in postnatal points. Vertical dashed line depicts birth. Y-axis depicts RPKM expression values. b, c UMAP representation of human embryo cells 4–5.5 weeks post conception. N = 7 embryos, 185k cells. b Left: Cells colored by neural progenitor cells annotated in the original study colored green. c Right: Cells colored by normalized expression of FGFR1. Color scale midpoint is set to the midpoint of maximum and minimum expression. d Detection rate (% of cells with expression >0) of FGFR1 expression in broad cell types of first trimester human brain. e Top 15 cell clusters by detection rate (% of cells with expression of >0) of Fgfr1 expression in developing mouse pons and forebrain. Cell clusters grouped by broad cell type. Credit: Nature Communications (2025). DOI: 10.1038/s41467-025-61820-z

A collaborative study between Dana-Farber Cancer Institute and the Broad Institute found that 8.9% of children with glioma, the most common form of pediatric brain tumor, have alterations in the fibroblast growth factor receptor (FGFR) family of proteins, and that these gliomas may be sensitive to existing U.S. Food and Drug Administration (FDA) approved inhibitors that broadly block FGFR.

The work opens the door to potential targeted therapy for these tumors, particularly for pediatric low-grade gliomas (pLGG), though more research is needed to improve the efficacy of these treatments and to test them in pediatric clinical trials. Currently there are no FDA-approved therapies or clinical trials specifically for FGFR-altered pediatric gliomas.

“This research was motivated by the patients we see in our Jimmy Fund Clinic and others around the world who have been diagnosed with pediatric gliomas with FGFR-alterations and want to know if existing targeted medicines are an option,” says co-senior author Pratiti (Mimi) Bandopadhayay, MBBS, PhD, a physician-scientist at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and an institute member at Broad.

“The results of this study have given us insights that will impact children with FGFR-altered gliomas seeking care in the clinic today.”

The research is published today in Nature Communications.

Similar research at Dana-Farber led to the recent approval of tovorafenib for childhood BRAF-altered gliomas.

“We’re following that same strategy with this research but with a focus on FGFR-altered pediatric gliomas,” says Bandopadhayay. “It is a real area of need for families.”

This study, which was also led by Dana-Farber pathologist and an associate member at Broad, Keith Ligon, MD, PhD, performed genomic analyses on 11,635 gliomas from three existing datasets across all ages. The analysis revealed that 8.9% of pediatric gliomas harbor FGFR alterations. The most common alterations found were in the FGFR1 and FGFR2 genes and included both point mutations and structural variants. The team concluded that FGFR1-altered pLGGs were the most frequent subgroup of FGFR-altered gliomas in children.

Co-first authors April Apfelbaum, PhD, and Eric Morin, MD, PhD, post-doctoral fellows in the Bandopadhayay lab, leveraged the genomic data to develop the first-ever models of FGFR-altered gliomas consisting of spherical collections of living FGFR-altered neural stem cells. They used the models to determine that FGFR alterations can induce the development of the tumors.

Tests of FGFR inhibitors in the preclinical models showed that the tumors were sensitive to the inhibitors.

“This is the first preclinical data showing that existing FGFR inhibitors might be viable therapeutics for FGFR-altered pediatric gliomas,” says Apfelbaum.

They followed their preclinical model tests with a retrospective look at a small number of cases of pediatric patients with FGFR-altered gliomas who were treated with FGFR inhibitors. They found that patients with pLGGs frequently experienced stable disease after treatment with these medicines.

PLGGs are the most common central nervous system cancer among children. Patients typically survive into adulthood after treatment because the tumors stop growing over time, but current standard treatment with chemotherapy and surgery result in long-term challenges including mental health disorders, vision changes or loss, seizures, and behavioral challenges.

“We are eager to find precision medicines with fewer side effects than current standard of care treatment for these patients,” says Bandopadhayay.

The team plans continued research to improve the efficacy and brain penetrance of FGFR inhibitors and to test these medicines in clinical trials. They also plan to investigate their finding that FGFR expression may play a role in normal brain development to determine if that finding should influence treatment strategies.

More information:
April A. Apfelbaum et al, A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas, Nature Communications (2025). DOI: 10.1038/s41467-025-61820-z

Provided by
Dana-Farber Cancer Institute


Citation:
New research shows promise for targeted therapies for pediatric gliomas (2025, July 31)
retrieved 31 July 2025
from https://medicalxpress.com/news/2025-07-therapies-pediatric-gliomas.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



Tags: Health ResearchHealth Research NewsHealth ScienceMedicine ResearchMedicine Research NewsMedicine Science
Previous Post

‘American Idol’ exec slaying and other break-ins spark call for action

Next Post

Will Congress help protect our beaches?

Related Posts

Rituximab not superior to conventional strategy for eosinophilic granulomatosis with polyangiitis

Rituximab not superior to conventional strategy for eosinophilic granulomatosis with polyangiitis

August 1, 2025
4
diabetes

Chronic inflammation biomarkers can influence treatment success

August 1, 2025
4
Next Post
beach-silhouette-vacation-shadow-together-lifestyle-927341-pxhere.com

Will Congress help protect our beaches?

  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Police ID man who died after Corso Italia fight

December 23, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0

Swimmer Megan Romano first female to join Enhanced Games todayheadline

August 1, 2025
PLTR Revenue (Quarterly) Chart

Palantir at All-Time Highs: Buy Now or Brace for a Reality Check? todayheadline

August 1, 2025

Prosus' $4.74 billion Just Eat Takeaway deal set for EU approval todayheadline

August 1, 2025

What Quiet Leadership Looks Like in a Loud World todayheadline

August 1, 2025

Recent News

Swimmer Megan Romano first female to join Enhanced Games todayheadline

August 1, 2025
2
PLTR Revenue (Quarterly) Chart

Palantir at All-Time Highs: Buy Now or Brace for a Reality Check? todayheadline

August 1, 2025
3

Prosus' $4.74 billion Just Eat Takeaway deal set for EU approval todayheadline

August 1, 2025
5

What Quiet Leadership Looks Like in a Loud World todayheadline

August 1, 2025
5

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Cybersecurity
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

Swimmer Megan Romano first female to join Enhanced Games todayheadline

August 1, 2025
PLTR Revenue (Quarterly) Chart

Palantir at All-Time Highs: Buy Now or Brace for a Reality Check? todayheadline

August 1, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co